Introduction: Hypernatremia is a common problem in hospitalized patients and is associated with high morbidity and mortality. This study was designed to evaluate whether physicians follow the recommended guidelines for the rate of correction of hypernatremia of Յ0.5 mEq/L/hr and to evaluate the effect of the rate of correction of severe hypernatremia on the mortality of hospitalized patients. Methods: A retrospective chart review of 131 consecutively hospitalized patients with severe hypernatremia (serum sodium Ն155 mEq/L) was performed. Primary outcomes were 30-day patient mortality and 72-hour hypernatremia correction. The first 24-hour serum sodium (Na ϩ ) correction rate was tested as a categorical variable; slow rate (Ͻ0.25 mEq/L/hr) and fast rate (Ն0.25 mEq/L/hr). Results: The mean admission serum Na ϩ level was 159 Ϯ 3 mEq/L. Ninety percent of patients received the recommended Ͻ0.5 mEq/L/hr serum Na ϩ correction rate; however, hypernatremia was corrected only in 27% of patients after 72 hours of treatment. Thirty-day patient mortality rate was 37%. In multivariable analysis, do not resuscitate status [hazards ratio (HR), 3.85; P Ͻ 0.0001], slower correction rate of hypernatremia (HR, 2.63; P ϭ 0.02) and high heart rate (Ͼ100 beats/min; HR, 1.99; P ϭ 0.03) were the independent predictors of 30-day mortality. Conclusion: In patients with severe hypernatremia, the rate of correction of hypernatremia was slow and resulted in inadequate correction in majority of the patients. Both slow rate of hypernatremia correction during the first 24 hours and do not resuscitate status were found to be significant predictors of 30-day patient mortality. H ypernatremia, defined as serum sodium (Na ϩ ) concentration Ͼ145 mEq/L, is a common electrolyte disorder in hospitalized patients. The incidence of hypernatremia was reported to be 1% to 3% in all hospitalized patients 1-3 and 9% in patients admitted in intensive care units (ICUs). 4 Hypernatremia has been proposed as a marker for concomitant infection, severe associated systemic illness and clinical neglect. 1, 5, 6 Reported mortality rates of patients with hypernatremia range from 42% to 60%. 1, [3] [4] [5] Previous studies demonstrated that the initial status of consciousness when hypernatremia was diagnosed, 7 concomitant sepsis or pneumonia 2,5,8 and increasing rates of fluids replacement 3 were important prognostic indicators of mortality. The hyperosmolar state associated with hypernatremia alters a variety of cellular functions, which contributes to metabolic, 9 neurologic 10 and cardiovascular 11 complications.
H ypernatremia, defined as serum sodium (Na ϩ ) concentration Ͼ145 mEq/L, is a common electrolyte disorder in hospitalized patients. The incidence of hypernatremia was reported to be 1% to 3% in all hospitalized patients [1] [2] [3] and 9% in patients admitted in intensive care units (ICUs). 4 Hypernatremia has been proposed as a marker for concomitant infection, severe associated systemic illness and clinical neglect. 1, 5, 6 Reported mortality rates of patients with hypernatremia range from 42% to 60%. 1, [3] [4] [5] Previous studies demonstrated that the initial status of consciousness when hypernatremia was diagnosed, 7 concomitant sepsis or pneumonia 2, 5, 8 and increasing rates of fluids replacement 3 were important prognostic indicators of mortality. The hyperosmolar state associated with hypernatremia alters a variety of cellular functions, which contributes to metabolic, 9 neurologic 10 and cardiovascular 11 complications.
The current study was designed to evaluate the effect of the rate of correction of severe hypernatremia on the mortality of hospitalized patients and to evaluate whether physicians follow the current recommendations for correction of hypernatremia. 10 
METHODS
This retrospective cohort study used computerized medical records of all patients admitted between January 2004 to December 2006 at the Veterans Affairs Medical Center in Memphis, TN, to identify patients with severe hypernatremia, defined as serum Na ϩ level Ն155 mEq/L. Inclusion criterion for the study was serum Na ϩ level Ն155 mEq/L at least once during admission or hospital stay. Exclusion criteria for the study were systolic blood pressure (SBP) Ͻ90 mm Hg and incomplete data. Of the 131 patients identified, 7 patients with missing data and 7 patients with hypotension were excluded from analysis, leaving 117 patients for analysis. Each patient's physician determined the management plan for hypernatremia. The following clinical information was obtained from patients' charts: race, sex, age, congestive heart failure (CHF), chronic kidney disease (CKD), diabetes mellitus (DM), neurologic impairment (defined as confusion at the time of diagnosis of hypernatremia), do not resuscitate (DNR) status, place of onset of hypernatremia (in hospital versus community acquired), admission to ICUs, admission to medicine versus surgical units, time of onset of hypernatremia (acute versus chronic hypernatremia), heart rate, SBP and diastolic blood pressure (DBP) at the time of diagnosis.
Patients with ejection fraction Ͻ40% on echocardiogram, or with signs, symptoms and radiologic evidence of pulmonary edema were considered as having CHF. Patients with serum Na ϩ levels Ն155 mEq/L in the admission data set were considered to have hypernatremia before hospitalization. Development of hypernatremia in less than 48 hours was considered as acute hypernatremia, and patients with no antecedent measurement of serum Na ϩ or development of hypernatremia for more than 48 hours were considered to have chronic hypernatremia. Mean arterial pressure (MAP) was calculated from the SBP and DBP recordings.
The following laboratory data were collected at the time of diagnosis of hypernatremia: plasma concentrations of Na ϩ , glucose, creatinine and blood urea nitrogen. Serum Na ϩ concentrations at 24, 48 and 72 hours after the diagnosis of hypernatremia were recorded, and hypernatremia correction rate per hour was calculated. Main outcomes were 30-day patient mortality and correction of hypernatremia (serum Na ϩ concentration Ͻ145 mEq/L) at 72 hours.
The study was approved by the institutional review board of the Veterans Affairs Medical Center at Memphis, TN.
Statistical Analysis
Continuous variables were presented as means and standard deviations, and categorical variables as percentages. Nonnormally distributed continuous variables were log transformed or changed into categorical variables. Univariate analysis for 30-day patient survival was performed for the following variables using Cox regression method: age, race, heart rate, MAP, DBP, serum creatinine concentration, initial serum Na ϩ concentration, admission to ICUs, admission to medicine versus surgical units, place of onset of hypernatremia, CHF, CKD, DM, neurologic impairment, DNR status, time of onset of hypernatremia and the rate of serum Na ϩ correction rate in the first 24 hours. Serum Na ϩ correction rate in the first 24 hours was tested as a categorical variable; the mid-point between the maximum recommended rate of correction (0.5 mEq/L) and no correction (0 mEq/L) was used as the cutoff value (slow rate: Ͻ0.25 mEq/L/hr versus fast rate: Ն0.25 mEq/L/hr). Age was grouped into quintiles: 26 to 59 (reference), 60 to 71, 72 to 80, 81 to 85 and 86 to 99 years. Heart rate [Ͻ100 and Ն100 beats/minute (bpm)], MAP (Ͻ70 and Ն70 mm Hg), DBP (Ͻ60 and Ն60 mm Hg) serum creatinine concentration (Ͻ1.5 and Ն1.5 mg/dL), race (black and white), admission in ICU (ICU and floor), place of onset (in hospital and community), CHF, CKD, DM, time of onset (acute hypernatremia and chronic hypernatremia), neurologic impairment and code status (DNR and full code) were included as binary variables in the model. The proportional hazard assumption for the predictor variables in the multivariate analysis was verified and met by examining the plots of Schoenfeld residuals. The estimated hazards ratio (HR) along with corresponding 95% confidence intervals and P values are reported for all regression covariates.
Serum Na ϩ concentrations and hypernatremia correction rates at different time intervals between 30-day survivors and nonsurvivors were compared using independent-samples t test for normally distributed and Mann-Whitney U test for nonnormally distributed data. Survival curves were produced by Kaplan-Meier method, and fast correction rate versus slow rate in the first 24 hours were compared by the log-rank test. Patients alive at the end of 30 days were censored. All tests were 2 sided, and a P value Ͻ0.05 was considered significant, unless otherwise stated. Statistical analysis was conducted using SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS
Demographic, clinical and laboratory characteristics of the patients are depicted in Tables 1 and 2 . In this cohort of 117 hypernatremic patients, 43 patients (37%) died within 30 days of diagnosis of hypernatremia. Ten patients died within 72 hours of diagnosis. Among the 107 patients who survived 72 hours, serum Na ϩ concentration returned to normal (Ͻ145 mEq/L) in 29 (27%) patients. Patients whose hypernatremia was corrected within 72 hours were more likely to be managed in ICU (89% versus 64%, P ϭ 0.0096), less likely to have DNR status (21% versus 42%, P ϭ 0.0295), had higher MAP (95 Ϯ 16 mm Hg versus 86 Ϯ 13 mm Hg, P ϭ 0.0029), had higher first 24-hour hypernatremia correction rate (0.39 Ϯ 0.32 mEq/ L/hr versus 0.07 Ϯ 0.20 mEq/L/hr) and had lower mortality (10% versus 39%, P ϭ 0.0048) compared with patients whose hypernatremia was not corrected within 72 hours. The mean baseline serum Na ϩ concentration was similar between the 2 groups (160 Ϯ 4 mEq/L versus 159 Ϯ 3 mEq/L, P ϭ 0.1499).
The mean first 24-hour hypernatremia correction rate for the entire cohort was 0.15 Ϯ 0.30 mEq/L/hr (range: Ϫ0.42 to 1.38 mEq/L/hr; Table 3 ). The mean 72-hour hypernatremia correction rate was 0.13 Ϯ 0.10 mEq/L/hr (range: Ϫ0.12 to 0.36 mEq/L/hr).
Hypernatremia correction rate in the first 24 hours was Ն0.25 mEq/L/hr in 39 (33%) patients and Ͻ0.25 mEq/L/hr in 78 (67%) patients. Seven of 39 patients in the faster rate correction group died within 30 days (mortality rate, 18%) compared with 36 of 78 patients (mortality rate, 46%) in the slower correction group (P ϭ 0.0029). The Kaplan-Meier survival estimate for the first 24-hour fast versus slow correction rate is shown in Figure 1 . The difference in mortality between the 2 correction rates by log-rank test was significant (P ϭ 0.0036).
Univariate Cox regression analysis showed statistically significant influence of the following variables on 30-day patient mortality (Table 4) : DNR status, slow hypernatremia correction rate in the first 24 hours, age Ͼ86 years, CHF, neurologic impairment, heart rate Ͼ100 bpm, MAP Ͻ70 mm Hg and DBP Ͻ60 mm Hg. These variables along with the interaction terms between DNR status and CHF with the first 24-hour serum hypernatremia correction rate were used in multivariable analysis with Cox proportional hazard regression model. The final model predicting 30-day patient mortality consisted of DNR status, slow serum Na ϩ correction rate in the first 24 hours and heart rate Ͼ100 bpm ( Table 5) .
The mean serum Na ϩ concentration at the time of diagnosis was similar between the survivor and nonsurvivor groups (159 Ϯ 4 mEq/L versus 158 Ϯ 2 mEq/L; Figure 2 ). However, the mean hypernatremia correction rate was found to be significantly higher in the survivor group compared with the nonsurvivor group at 24 hours (0. Compared with patients with full code status, patients with DNR status were significantly older (78 Ϯ 12 years versus 69 Ϯ 13 years, P Ͻ 0.0003), had lower first 24-hour serum Na ϩ correction rate (0.05 Ϯ 0.23 mEq/L/hr versus 0.21 Ϯ 0.33 mEq/L/hr, P Ͻ 0.01), higher likelihood of neurologic impairment (66% versus 37%, P Ͻ 0.002) and higher 30-day mortality (61% versus 20%, P Ͻ 0.0001). There were no significant differences in the presence of CHF, and DM, level of MAP or the initial serum concentrations of Na ϩ and creatinine between the 2 groups.
In the current study, 24 patients (20%) had acute hypernatremia and 93 patients (80%) had chronic hypernatremia. Thirty-day mortality was lower in patients with acute hypernatremia compared with patients with chronic hypernatremia but not statistically significant (21% versus 41%, respectively, P ϭ 0.0962). Initial mean serum Na ϩ concentration was similar between the 2 groups (159 Ϯ 3 mEq/L versus 159 Ϯ 3 mEq/L). Patients with acute hypernatremia received faster rate of hypernatremia correction (0.36 Ϯ 0.48 mEq/L/hr) compared with patients with chronic hypernatremia (0.09 Ϯ 0.21 mEq/ L/hr). The correction rate was Ն0.5 mEq/L/hr in 11 patients with acute hypernatremia and 1 patient with chronic hypernatremia. As a result of this, after 72 hours, the mean serum Na ϩ concentration returned to normal (144 Ϯ 7 mEq/L) in the acute hypernatremia group, but remained increased in the chronic hypernatremia group (150 Ϯ 5 mEq/L). Hypernatremia was corrected within 72 hours in 57% of patients with acute hypernatremia compared with 19% of patients with chronic hypernatremia.
In our analysis, we did not observe any significant difference between patients with hospital-acquired and community-acquired hypernatremia in terms of serum Na ϩ concentration and serum Na ϩ correction rate at different time intervals or 30-day mortality.
DISCUSSION
The goal of management of hypernatremia is to correct the water deficit in a reasonable time frame while avoiding untoward adverse effects associated with treatment. In the current study, hypernatremia was corrected within 72 hours of onset in only 36% of patients. The correction rate was higher (47%) in the study by Palevsky et al. 1 Although patients included in that study had less severe hypernatremia, as lower serum Na ϩ concentration cutoff value (Ͼ150 mEq/L) was used as the inclusion criteria for the study.
In patients with chronic hypernatremia or in cases where the duration of hypernatremia is unknown, rapid correction of the water deficit should be avoided. In this situation correction of hypernatremia over a period of 2 to 3 days has been recommended, 1 with a maximum serum Na ϩ correction rate of 0.5 mEq/L/hr, or a decrease in serum Na ϩ level of 10 to 12 mEq/L in a given 24-hour period. 10 -14 There are no prospective human studies to fully validate these recommendations; however, animal studies suggest that this rate of correction reflects the observed rate of cerebral de-adaptation. 10, 12, 15 Almost all of the patients with chronic hypernatremia (n ϭ 93) in the current study received serum Na ϩ correction rate of Ͻ0.5 mEq/L/hr. However, chronic hypernatremia was corrected within 72 hours only in 19% of these patients. In contrast, hypernatremia can be corrected promptly in cases of acute hypernatremia: with rate of correction as high as 1 mEq/L/hr, without the need for gradual correction over 2 to 3 days. The mean hypernatremia correction rate in the first 24 hours among patients with acute hypernatremia (n ϭ 24) was 0.36 Ϯ 0.48 mEq/L/hr. This resulted in correction of hypernatremia within 72 hours in 57% of patients with acute hypernatremia.
The 30-day patient mortality rate in the current study was 37%. In previous studies, the mortality of patients with hypernatremia varied from 41% to 66% among all hospitalized patients 1, 3, 16 and 29.5% to 46.2% among patients admitted in ICUs. 4, 17 Nonsurvivors in the current study had significantly high 72-hour serum Na ϩ concentrations. Possible reasons for the persistently increased serum Na ϩ concentration include delayed diagnosis of hypernatremia, late fluid replacement after diagnosis, administration of normal saline for hypotension and inappropriate adjustment of the rate or type of fluid administration during follow-up. We have observed a possible association between the slower first 24-hour hypernatremia correction rate and 30-day patient mortality. Patients with first 24-hour hypernatremia correction rate Ͻ0.25 mEq/L/hr had significantly higher mortality (HR, 2.63; P ϭ 0.0198) and higher serum Na ϩ concentration at 72 hours. Reason for this association is not clear. Mandal et al 16 in their study of patients similar to the current study cohort found a significant association between the persistently increased serum Na ϩ concentration and patient mortality. The increased serum Na ϩ level in the nonsurvivor group in their study was attributed to the continuous infusion of normal saline. Mandal et al also found significantly higher number of patients in the nonsurvivor group with DBP Ͻ60 mm Hg during hospital course. This raised the possibility of interaction between the serum Na ϩ concentration and low DBP in the study. In the current study, we excluded patients with low blood pressure (SBP Ͻ90 mm Hg) at the time of diagnosis of hypernatremia because these balt5/z7a-maj/z7a-maj/z7a99910/z7a4024-10z xppws S‫1؍‬ 12/27/10 3:44 Art: MAJ201257 Input-rk patients were more likely to receive fluid resuscitation with normal saline. For the patients who were included in the study, MAP Ͻ70 mm Hg or DBP Ͻ60 mm Hg did not contribute to the multivariable model of the 30-day patient mortality in the Cox proportional hazard analysis.
Patients with DNR status in the study had significantly higher mortality rate compared with patients without the DNR status despite similar degree of initial hypernatremia. Patients with terminal medical conditions are more likely to have advance directives indicating DNR status, which may account for the increased mortality. The presence of the DNR status may also influence physician's behavior, including the aggressiveness of fluid resuscitation and hypernatremia management. In the current study, patients with DNR status received significantly slower first 24-hour serum Na ϩ correction rates. The current study found no difference in mortality between patients developing hypernatremia before or after hospital admission. Similar findings were reported by Palevsky et al, 1 although 2 previous studies reported a significantly higher mortality rate in patients with hospital-acquired hypernatremia compared with those with community-acquired hypernatremia. 3, 16 The acuteness of development of hospital-acquired hypernatremia and associated comorbid illness in those patients was put forward as a possible explanation for the higher mortality in patients with hospital-acquired hypernatremia.
Limitations of the current study include the retrospective observational cohort study design. Thus, we cannot rule out the effect of additional unmeasured confounders on patients' mortality. On the other hand, retrospective design was necessary for the study to determine physicians' adherence to hypernatremia correction guideline. We are also not able to put forward a plausible explanation for the association between the rate of correction of hypernatremia and 30-day patient mortality. It is not clear from the available data whether the association indicates a direct effect of hypernatremia or a reflection of nonaggressive medical care. Detailed information about the fluid management is not available in our study. This information might help to explain reasons for slow hypernatremia correction rate in some patients. The study was performed in a single center, and 98% of patients were men, which may limit generalizability of study results.
CONCLUSION
In conclusion, this study showed that correction of hypernatremia was slow in patients with severe hypernatremia. The majority of the patients' serum Na ϩ concentration in the study remained above the normal range even after 72 hours of treatment. This illustrates the importance of early identification and institution of appropriate treatments for hypernatremia in these patients. The association between the slow rate of hypernatremia correction and 30-day mortality in this study emphasizes the need for future prospective trials to explore a possible causal relationship.
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